

bluebird Pipeline Overview

Product Candidates	Program Area	Preclinical	Phase 1/2	Phase 2/3	Rights/Partner
	CNS Diseases				
Lenti-D™ Drug Product	Cerebral ALD				Worldwide
	Rare Hemoglobinopathies				
LentiGlobin® Drug Product	Transfusion-Dependent β-thalassemia*			(Phase 3)	Worldwide
	Severe Sickle Cell Disease				Worldwide
	Oncology				
bb2121 BCMA	Multiple Myeloma				Celgene
Next Gen BCMA	Multiple Myeloma				Celgene
Five Prime Target	Undisclosed				Worldwide
HPV-16 E6 TCR	HPV-associated Cancers				Kite Pharma
Viromed Target	Undisclosed				Worldwide excluding Korea
Medigene Targets	Undisclosed				Worldwide
Other Programs	Undisclosed				Worldwide
	Research				
Early Pipeline	Undisclosed + Gene Editing				Worldwide

*The current clinical trials for LentiGlobin are Phase 1/2 studies that may provide the basis for early conditional approval in some jurisdictions

COLLABORATORS

